Press Releases
Newsroom
Press Releases from NPA
2026
World-Leading Neuroplasticity Researcher Dr. Steven Cramer, M.D., MSc., Joins NPA's Scientific Advisory Board
LOUISVILLE, KY— The Neuroplasticity Alliance (NPA) is honored to announce that Dr. Steven C. Cramer, M.D., MSc. — one of the world's most influential researchers in stroke recovery and neuroplasticity — has joined its Scientific Advisory Board.
.png)
Louisville Physician Dr. Ali Farooqui, M.D., Joins NPA's Board of Directors
LOUISVILLE, KY— The Neuroplasticity Alliance (NPA) today announced the appointment of Ali A. Farooqui, M.D., to its Board of Directors. Dr. Farooqui, M.D. is a managing partner at Integrative Psychiatry and the Kentucky Center for Advanced Neuromodulation, medical director and founding partner of Healthy Minds Tennessee...
NPA Welcomes Renowned Stroke Recovery Pioneer Dr. Seth P. Finklestein, M.D. to Scientific Advisory Board
LOUISVILLE, KY – May 22, 2026: The Neuroplasticity Alliance (NPA), a leading nonprofit organization dedicated to bridging the gap between cutting-edge neurological research and mainstream clinical care, today announced the appointment of Dr. Seth P. Finklestein, M.D., to its Scientific Advisory Board.
2025
NPA Welcomes Dr. Martin M. Bednar, M.D., Ph.D., FAANS, as Chair of Scientific Advisory Board
Atlanta, GA – August 14, 2025: The Neuroplasticity Alliance (NPA) is proud to announce the appointment of Martin M. Bednar, M.D., Ph.D., FAANS, as Chair of its Scientific Advisory Board (SAB), effective September 1, 2025. A globally recognized leader in neuroscience, Dr. Bednar brings over three decades of clinical, academic, and industry experience to lead the development and strategy of NPA’s SAB.
2020
NPA Announces Launch to Accelerate Transformative Treatment Approach for Brain Dysfunction
Atlanta, GA – April 28, 2020: The Neuroplasticity Alliance (NPA) today announces the launch of a new not-for-profit focused on accelerating development of neuroplastic treatments and their integration into the healthcare system. These treatments target the root cause of neurologic disorders.